Clinical application guideline for mycophenolate sodium in liver transplant recipients in China(2024 edition)

doi:10.3877/cma.j.issn.1674-3903.2024.06.005

Abstract

Abstract:

Liver transplantation is an effective treatment for end-stage liver diseases, and an appropriate immunosuppressive regimen is fundamental to ensuring the long-term survival of both the graft and the recipient.Mycophenolic acid (MPA) derivatives are integral components of the basic immunosuppressive regimen for liver transplantation recipients.Mycophenolate sodium (MPS), the sodium salt of MPA, is used for the prevention of rejection in liver transplantation and the optimization of immunosuppressive protocols.The Liver Transplantation Group, Branch of Organ Transplantation of Chinese Medical Association, and Branch of Organ Transplant Physicians of Chinese Medical Doctor Association organized experts to summarize and discuss the mechanism, clinical applications, and considerations for the use of MPS in combination with international guidelines and clinical practice,aiming to provide guidance and suggestions for the clinical application of MPS in liver transplant recipients.

Key words: Liver transplantation, Immunosuppressant, Mycophenolate sodium, Maintenance therapy, Acute rejection reaction

Transplantation Group, Branch of Organ Transplantation of Chinese Liver, of Organ Transplant Physicians of Chinese Branch. Clinical application guideline for mycophenolate sodium in liver transplant recipients in China(2024 edition)[J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 366-373.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2024.06.005

https://zhyzzz.cma-cmc.com.cn/EN/Y2024/V18/I06/366

Figures/Tables 2

References 62

1	Ronca V, Wootton G, Milani C, et al.The immunological basis of liver allograft rejection[J].Front Immunol,2020,11:2155.
2	Rath T, Küpper M.Comparison of inosine-monophosphatedehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation [J].Transplant Proc,2009,41(6):2524-2528.
3	Klaasen RA, Bergan S, Bremer S, et al.Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation[J].Br J Clin Pharmacol,2020,86(6):1100-1112.
4	Arns W, Gies M, Choi L, et al.Absorption characteristics of EC-MPS-an enteric-coated formulation of mycophenolic sodium[J].Int J Clin Pharmacol Ther,2006,44(8):375-385.
5	Wang Z, He JJ, Liu XY, et al.The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China[J].Immunopharmacol Immunotoxicol, 2015, 37(6):508-512.
6	Pawinski T, Luszczynska P, Durlik M, et al.Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus[J].Ther Drug Monit,2013,35(6):760-769.
7	Bowalgaha K, Miners JO.The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes[J].Br J Clin Pharmacol,2001,52(5):605-609.
8	王鹤, 孙丽莹.肝移植后抗体介导的排斥反应诊治进展[J/CD].实用器官移植电子杂志,2022,10(04):368-371.
9	中国医师协会器官移植医师分会,中华医学会器官移植学分会,中华医学会外科学分会移植学组,等.中国心脏死亡捐献器官评估与应用专家共识(2022 版)[J/CD].中华移植杂志:电子版,2022,16(6):321-328.
10	Nelson J, Alvey N, Bowman L, et al.Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation,and the International Society for Heart and Lung Transplantation[J].Pharmacotherapy,2022,42(8):599-633.
11	Kato T, Gaynor JJ, Yoshida H, et al.Randomized trial of steroidfree induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year[J].Transplantation, 2007, 84(7): 829-835.
12	Wiesner RH, Steffen BJ, David KM, et al.Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients[J].Am J Transplant,2006,6(7):1609-1616.
13	Martín-Mateos RM, Graus J, Albillos A, et al.Initial immunosuppression with or without basiliximab: a comparative study[J].Transplant Proc,2012,44(9):2570-2572.
14	Nure E, Magalini SC, Frongillo F, et al.Enteric-coated mycophenolate sodium: one-way conversion from mycophenolate mofetil and de novo use in stable liver transplant recipients[J].Transplant Proc,2009,41(4):1290-1292.
15	Sunderland A, Russ G, Sallustio B, et al.Effect of the proton-pump Inhibitor pantoprazole on mycophenolic acid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial[J].Nephrol Dial Transplant,2020,35(6):1060-1070.
16	中华医学会器官移植学分会,中国医师协会器官移植医师分会.中国肝移植受者肾损伤管理临床实践指南(2023 版)[J/CD].中华移植杂志:电子版,2023,17(6):321-331.
17	TruneCˇka P, Klempnauer J, Bechstein WO, et al.Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study[J].Am J Transplant,2015,15(7):1843-1854.
18	Tan PS, Muthiah MD, Koh T, et al.Asian liver transplant network clinical guidelines on immunosuppression in liver transplantation[J].Transplantation,2019,103(3):470-480.
19	Neuberger JM, Mamelok RD, Neuhaus P, et al.Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study[J].Am J Transplant,2009,9(2):327-336.
20	Saliba F, Duvoux C, Gugenheim J, et al.Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial[J].Am J Transplant,2017,17(7):1843-1852.
21	Cantisani GP, Zanotelli ML, Gleisner AL, et al.Enteric-coated mycophenolate sodium experience in liver transplant patients[J].Transplant Proc,2006,38(3):932-933.
22	Durand F.Hot-topic debate on kidney function: renal-sparing approaches are beneficial[J].Liver Transpl, 2011, 17(Suppl 3):S43-S49.
23	Dharancy S, Iannelli A, Hulin A, et al.Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation[J].Am J Transplant,2009,9(3):610-613.
24	Lassailly G, Dumortier J, Saint-Marcoux F, et al.Real life experience of mycophenolate mofetil monotherapy in liver transplant patients[J].Clin Res Hepatol Gastroenterol, 2021, 45 (1):101451.
25	Jiménez-Pérez M, Lozano Rey JM, Marín García D, et al.Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation[J].Transplant Proc,2006,38(8):2480-2481.
26	Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, et al.Mycophenolate mofetil can be used as monotherapy late after liver transplantation[J].Am J Transplant,2004,4(10):1650-1655.
27	Orlando G, Baiocchi L, Cardillo A, et al.Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension[J].Liver Transpl,2007,13(1):46-54.
28	中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组.中国肝移植受者代谢病管理专家共识(2019 版)[J/CD].中华移植杂志:电子版,2019,13(3):187-194.
29	Lim WH, Tan C, Xiao J, et al. De novo metabolic syndrome after liver transplantation: a meta-analysis on cumulative incidence, risk factors, and outcomes[J].Liver Transpl,2023,29(4):413-421.
30	Song JL, Li M, Yan LN, et al.Higher tacrolimus blood concentration is related to increased risk of post-transplantation diabetes mellitus after living donor liver transplantation[J].Int J Surg,2018,51:17-23.
31	中华医学会器官移植学分会, 中国医疗保健国际交流促进会肾脏移植学分会.中国肾脏移植长期健康管理指南(2023 版)[J].中华器官移植杂志,2024,45(5):283-298.
32	Herrero JI, Quiroga J, Sangro B, et al.Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus[J].Transplant Proc,2003,35(5):1877-1879.
33	Wei Q, Gao F, Zhuang R, et al.A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J].Chin J Cancer Res, 2017, 29(5):426-437.
34	Albano L, Alamartine E, Toupance O, et al.Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study[J].Ann Transplant,2012,17(1):58-67.
35	中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组.中国肝癌肝移植临床实践指南(2021 版)[J/CD].中华移植杂志:电子版,2021,15(6):321-328.
36	Zahn A, Müeller F, Hinz U, et al.Mycophenolate mofetil combination therapy improves survival after liver transplantation.a single-center retrospective analysis[J].Ann Transplant, 2013, 18:525-532.
37	Abrahamsson J, Sternby Eilard M, Rizell M, et al.Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation [J].Scand J Gastroenterol,2022,57(3):325-332.
38	Kang SH, Hwang S, Ha TY, et al.Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma[J].Korean J Hepatobiliary Pancreat Surg,2014,18(2):48-51.
39	刘东岳,姜英俊, 饶伟, 等.肝移植受者上消化道疾病的流行病学及影响因素[J/CD].实用器官移植电子杂志, 2019, 7(2):144-147.
40	Savvidaki E,Papachristou E,Kazakopoulos P,et al.Gastrointestinal disorders after renal transplantation[J].Transplant Proc, 2014, 46(9):3183-3186.
41	Telkes G, Peter A, Tulassay Z, et al.High frequency of ulcers, not associated with Helicobacter pylori, in the stomach in the first year after kidney transplantation[J].Nephrol Dial Transplant, 2011, 26(2):727-732.
42	Pallet N, Anglicheau D, Martinez F, et al.Comparison of sequential protocol using basiliximab versus antithymocyte globulin with highdose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor[J].Transplantation, 2006, 81(6): 949-952.
43	Herrero JI, Benlloch S, Bernardos A, et al.Gastrointestinal complications in liver transplant recipients: MITOS study [J].Transplant Proc,2007,39(7):2311-2313.
44	Pelletier RP, Akin B,Henry ML,et al.The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation[J].Clin Transplant,2003,17(3):200-205.
45	中华医学会器官移植学分会.器官移植免疫抑制剂临床应用技术规范(2019 版)[J].器官移植,2019,10(3):213-226.
46	Dumortier J, Gagnieu MC, Salandre J, et al.Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study[J].Liver Transpl,2006,12(9):1342-1346.
47	Robaeys G, Cassiman D, Verslype C, et al.Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium(myfortic) in liver transplant patients with gastrointestinal side effects[J].Transplant Proc,2009,41(2):610-613.
48	Sterneck M, Settmacher U, Ganten T, et al.Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients[J].Transplant Proc,2014,46(1):234-240.
49	Lopez-Solis R, DeVera M,Steel J,et al.Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs.mycophenolate mofetil[J].Clin Transplant, 2014, 28(7):783-788.
50	Toledo AH, Hendrix L, Buchholz V, et al.Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients[J].Clin Transplant,2012,26(1):156-163.
51	林立敏, 卢克鹏, 刘倩, 等.霉酚酸酯在肝移植术后免疫抑制治疗中有效性和安全性的系统评价[J].中国医院药学杂志,2015,35(1):44-50.
52	Novartis Pharma Schweiz AG.Mycophenolate sodium enteric-coated tablets (Myfortic) package insert[EB/OL].(2022-03-15)[2024-12-10].https:/ /www.accessdata.fda.gov/drugsatfda_docs/label/2022/050791s035lbl.pdf#page=23.
53	Khan F, Syed F, AbdulMuthalib H, et al.Fetal malformations associated with exposure to mycophenolic acid during the first trimester[J].Int J Pediatr Adolesc Med,2022,9(3):171-173.
54	Martin-Moreno PL, Sánchez-Fructuoso AI, Mazuecos A, et al.Paternal safety of the use of mycophenolic acid in kidney transplant recipients.Results of the EMVARON study[J].Clin Transplant,2021,35(5): e14256.
55	Guide for healthcare providers cellcept(mycophenolate mofetil) risk of teratogenicity[EB/OL].(2023-08) [2024-12-10].https:/ /www.sfda.gov.sa/sites/default/files/2024-04/CELLCEPT% 20%28MYCOPHENOLATE%20MOFETIL% 29% 20GUIDE% 20FOR%20HCPs%20v%202.0.1.pdf.
56	Bakris GL, Agarwal R, Anker SD, et al.Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J].N Engl J Med,2020,383(23):2219-2229.
57	Habet S.Narrow Therapeutic Index drugs: clinical pharmacology perspective[J].J Pharm Pharmacol,2021,73(10):1285-1291.
58	Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group.KDIGO clinical practice guideline for the care of kidney transplant recipients[J].Am J Transplant,2009,9(Suppl 3): S1-S155.
59	Harrison JJ, Schiff JR, Coursol CJ, et al.Generic immunosuppression in solid organ transplantation: a Canadian perspective[J].Transplantation,2012,93(7):657-665.
60	Alloway RR, Isaacs R, Lake K, et al.Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants[J].Am J Transplant,2003,3(10):1211-1215.
61	van Gelder T; ESOT Advisory Committee on Generic Substitution.European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs[J].Transpl Int,2011,24(12):1135-1141.
62	Uber PA, Ross HJ, Zuckermann AO, et al.Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory[J].J Heart Lung Transplant,2009,28(7):655-660.

推荐强度	证据等级	描述
A	1a	RCTs 的系统评价
	1b	结果可信区间小的RCT
	1c	显示“全或无效应”的任何证据
B	2a	队列研究的系统评价
	2b	单个队列研究(包括低质量RCT,如失访率>20%者)
	2c	基于患者结局的研究
	3a	病例对照研究的系统评价
	3b	单个病例对照研究
C	4	病例报道、低质量队列研究和低质量病例对照研究
D	5	专家意见(即无临床研究支持的仅依据基础研究或临床经验的推测)

推荐强度	证据等级	描述
A	1a	RCTs 的系统评价
	1b	结果可信区间小的RCT
	1c	显示“全或无效应”的任何证据
B	2a	队列研究的系统评价
	2b	单个队列研究(包括低质量RCT,如失访率>20%者)
	2c	基于患者结局的研究
	3a	病例对照研究的系统评价
	3b	单个病例对照研究
C	4	病例报道、低质量队列研究和低质量病例对照研究
D	5	专家意见(即无临床研究支持的仅依据基础研究或临床经验的推测)

项目	MPS	MMF
推荐剂量	720 mg (4 片×180 mg/ 片),2 次/ d	1 000 mg (4 片×250 mg/ 片),2 次/ d
药物成分	麦考酚钠	吗替麦考酚酯
分子结构
分子量	319. 31	433. 49
活性成分	MPA	MPA
代谢副产物	钠盐	羟乙基吗啉
代谢副产物是否有肠道黏膜刺激性	无	有

项目	MPS	MMF
推荐剂量	720 mg (4 片×180 mg/ 片),2 次/ d	1 000 mg (4 片×250 mg/ 片),2 次/ d
药物成分	麦考酚钠	吗替麦考酚酯
分子结构
分子量	319. 31	433. 49
活性成分	MPA	MPA
代谢副产物	钠盐	羟乙基吗啉
代谢副产物是否有肠道黏膜刺激性	无	有

[1]	of Organ Transplantation of Chinese Medical Association Branch. Guideline on the clinical application of ex situ liver machine perfusion [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 334-345.
[2]	Transplantation Group, Branch of Organ Transplantation of Chinese Liver, of Organ Transplant Physicians of Chinese Branch. Chinese guideline for clinical application of antithymocyte globulin in liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 346-354.
[3]	Transplantation Group, Branch of Organ Transplantation of Chinese Liver, of Organ Transplant Physicians of Chinese Branch. Chinese clinical guideline for the diagnosis and treatment of sarcopenia in liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 355-365.
[4]	Ningning Hu, Yanrong Zhao, Dong Wang, Shengliang Wang, Yuan Guo. The correlation study between the expression of FMNL3 and prognosis in hepatocellular carcinoma liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 283-288.
[5]	Fushun Zhong, Lu Yu, Xiaoli Fan, Qifa Ye. Liver transplantation for the treatment of hepatic epithelioid hemangioendothelioma：a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 293-297.
[6]	Ranjia Liu, Xiangli Cui, Xiaozhu Zhou, Wei Qu, Zhijun Zhu. A systematic review of health-related quality of life assessment for pediatric liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 302-309.
[7]	Jian He, Li Zhang, Honghai Wang, Wentao Jiang. Research progress on the prognosis and treatment of hypersplenism after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 310-314.
[8]	Hanzhi Xu, Xun Qiu, Kai Wang, Xiao Xu. Study of defatting strategy for steatotic donor livers [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 18-24.
[9]	. Clinical status of laparoscopic living donor liver resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 30-35.
[10]	of Organ Transplant of China Medical Association Branch, of Organ Transplant Physicians of Chinese Medical Doctor Association Branch. Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after liver transplantation (2024 edition) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 1-12.
[11]	of Organ Transplantation of Chinese Medical Association Branch. Chinese practice guidelines for diagnosis and treatment of ischemic-type biliary lesion after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 739-748.
[12]	Zhihong Wei, Jianyong Liu, Xiaoya Wu, Fang Yang, Lizhi Lyu, Yi Jiang, Qiucheng Cai. Diagnosis and treatment of acute graft-versus-host disease after liver transplantation （report of four cases） [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 846-851.
[13]	Binsheng Fu, Xiao Feng, Qing Yang, Kaining Zeng, Jia Yao, Hui Tang, Jianrong Liu, Xuxia Wei, Huimin Yi, Shuhong Yi, Guihua Chen, Yang Yang. Application of donor liver with steatosis in adult split liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 789-794.
[14]	Chinese Society of Organ Transplantation of Chinese Medical Association, Surgery Group of Chinese Society of Surgery of Chinese Medical Association, Transplantation Group of Chinese Society of Surgery of Chinese Medical Association, South China Alliance of Split Liver Transplantation. Chinese Clinical Practice Guidelines on Split Liver Transplantation in Children [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 593-601.
[15]	Jun Liu, Wenjing Qiu, Fanghao Sun, Songying Li, Shuhong Yi, Binsheng Fu, Yang Yang, Hui Luo. Comparison of in vivo and in vitro split liver transplantation in pediatric liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 688-693.

Please choose a citation manager

Content to export